FRIEDMAN PAUL A

Director Paul A Friedman sold 24.5K shares for $12.8M across 28 transactions on 2026-01-09; stock has fallen 13.6% in 30 days.

Paul A Friedman, a director at Madrigal Pharmaceuticals, executed 28 separate sales totaling 24,520 shares for $12,808,956.92 on 2026-01-09, reducing his holdings by 11.6%. The blended average transaction price was $522.39, but the stock is now trading at $493.90, down 13.6% over the past 30 days and down 18.1% from its 52-week high of $602.83. This large block liquidation comes as the company remains unprofitable (net income of $-114,190,000.00 in the most recent period) despite generating $287,268,000.00 in revenue. His prior sales at this ticker over the last month have corresponded with declines, though the current stock movement post-transaction cannot yet be fully assessed.

MDGL Director Friedman sells 24,800 shares for $13.7M in 9 transactions; holds 187.2K shares post-sale.

Director Paul A. Friedman executed 9 separate sales totaling 24,800 shares for $13,694,157.81 on 2025-12-10, reducing his holdings from 212.0K to 187.2K shares (an 11.7% reduction). The blended average sale price of $552.18 sits within the 52-week range of $267.56–$601.03, and the stock currently trades at $571.44, representing a +3.4% move above his average execution price since the sale. His prior 5 sales at MDGL all experienced positive 90-day returns (ranging from +44.6% to +49.1%), indicating his historical sell timing at this ticker has been poorly timed relative to subsequent price appreciation. The company is unprofitable (net income of $-114.2M in the latest quarter) despite $287.3M in quarterly revenue, a fundamental backdrop that contextualizes the scale and structure of this insider liquidation.

Director Paul A Friedman sells 46,808 shares of MDGL for $16,631,386.12 in 12 transactions over Aug 11-12

Paul A Friedman, a Director at Madrigal Pharmaceuticals, executed 12 separate sales totaling 46,808 shares for $16,631,386.12 across August 11–12, 2025, at prices ranging from $350.19 to $359.81 (blended average $355.31). This represents a -20.0% reduction in his post-transaction holdings of 187,164 shares from a pre-transaction position of 233,972 shares. The sales occurred at prices well below the current market price of $373.46 and near the 52-week high range ($202.48–$373.46). The company's fundamentals show quarterly revenue of $212,802,000 but net income of negative $42,281,000 with a market cap of $8,324,055,168.44. Friedman's prior same-ticker history shows 5 prior trades (all sells on 2025-08-13), all of which have outcome data not yet measurable; his cross-ticker track record across 20 prior sells shows no well-timed exits at the 90-day mark.

MDGL Director Paul A Friedman sells 129,172 shares for $47,825,149.35 on 2025-08-13; 5 similar sells on 2025-08-12.

Director Paul A Friedman executed 17 separate sales of 129,172 shares totaling $47,825,149.35 on 2025-08-13, reducing his holdings by 40.8% from 316,336 to 187,164 shares. This large liquidation occurred at prices ranging from $358.23 to $374.38 with a blended average of $370.24, near the current price of $373.46 and at the 52-week high of $373.46. The filing follows 5 separate sales by the same insider on 2025-08-12, suggesting an intentional, multi-day disposition program. Given that the company reported negative net income of $-42,281,000.00 in its latest quarter and remains unprofitable on a full-year basis, this substantial director selling occurs against a backdrop of ongoing operational losses despite strong recent stock appreciation (+16.8% over 30 days, +28.0% over 90 days).

Director Friedman sells 28,876 shares ($10.2M) across 9 transactions at $350.10–$356.62, reducing holdings 13.4%; stock unprofitable, down 6.1% from 52-week high.

Paul A. Friedman, Director at Madrigal Pharmaceuticals, executed 9 separate sales totaling 28,876 shares for $10,198,844.04 across July 16–17, 2025, at a blended average price of $353.19. This represents a 13.4% reduction in his post-transaction holdings to 187,164 shares. The company is unprofitable (net income $-73,238,000.00 in the latest quarter) and trades at $334.13 today, 6.1% below its 52-week high of $355.88. Notably, Friedman's prior 5 sales at MDGL (all on 2024-04-08) showed a 0% well-timed rate at the 90-day mark—every prior sale was followed by positive stock returns, indicating historically poor exit timing at this ticker. The stock is up 18.2% over the past 30 days and 10.8% over 90 days, yet current price has retreated from transaction levels, creating a modest mark-to-market loss on the most recent tranche.